{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:52:17Z","timestamp":1786114337458,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SFB 1709\/1 2025 \\u2013 533056198"],"award-info":[{"award-number":["SFB 1709\/1 2025 \\u2013 533056198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.027","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:42:29Z","timestamp":1780501349000},"page":"4687-4707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Depletion of CD8+ CART cells leads to superior anti-tumor efficacy of pure CD4+ CART cells against acute leukemias"],"prefix":"10.1016","volume":"34","author":[{"given":"Qian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sedloev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Depke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Unglaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Jayavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-324X","authenticated-orcid":false,"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.027_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.027_bib3","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.05.027_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s44222-023-00031-x","article-title":"Optimizing the manufacturing and antitumour response of CAR T therapy","volume":"1","author":"Liu","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.ymthe.2026.05.027_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4(+) Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.027_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005878","article-title":"CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses","volume":"11","author":"Bove","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.027_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2026.05.027_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.027_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.05.027_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib18","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/cancers13174301","article-title":"Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models","volume":"13","author":"Csapl\u00e1r","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.05.027_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188439","article-title":"The outstanding antitumor capacity of CD4(+) T helper lymphocytes","volume":"1874","author":"Li","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.027_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.gpb.2019.03.002","article-title":"Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed T(H)1\/T(H)2 Response Independent of Differentiation","volume":"17","author":"Xhangolli","year":"2019","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.05.027_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1209","article-title":"TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance","volume":"9","author":"Yang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.027_bib25","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1158\/0008-5472.CAN-07-1141","article-title":"Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells","volume":"67","author":"Moeller","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.027_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellimm.2010.02.008","article-title":"Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy","volume":"262","author":"Brown","year":"2010","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib27","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1182\/blood-2004-12-4906","article-title":"Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection","volume":"106","author":"Moeller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.027_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/2326-6066.CIR-14-0195","article-title":"Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells","volume":"3","author":"Liadi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.05.027_bib30","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4(+) CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.027_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007803","article-title":"CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.027_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed\/Refractory Large B-Cell Lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.027_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.027_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2026.05.027_bib35","article-title":"A major role for CD4(+) T cells in driving cytokine release syndrome during CAR T cell therapy","volume":"4","author":"Boulch","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.05.027_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.027_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj2820","article-title":"Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL","volume":"8","author":"Bai","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.05.027_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.027_bib39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib40","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/bloodadvances.2023012463","article-title":"Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy","volume":"8","author":"Han","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.05.027_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.027_bib42","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2026.05.027_bib43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/mt.2012.210","article-title":"T cells redirected to EphA2 for the immunotherapy of glioblastoma","volume":"21","author":"Chow","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.027_bib44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.027_bib45","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.027_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","article-title":"Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial","volume":"16","author":"Schubert","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.027_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.027_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","article-title":"Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms","volume":"588","author":"Jayavelu","year":"2020","journal-title":"Nature"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:46:07Z","timestamp":1785962767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626004715"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.027","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depletion of CD8+ CART cells leads to superior anti-tumor efficacy of pure CD4+ CART cells against acute leukemias","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}